Phaseline

Companies › BeiGene

BeiGene: clinical trials, targets and expected readouts

6 active drug programs in 19 registered trials: 9 Phase 2, 7 Phase 1, 3 Phase 3; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tislelizumab (A317)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Non Small Cell Lung Cancer; Urothelial Carcinoma; Non-small Cell Lung Cancer; MSI-H/dMMR Solid Tumors …Nov 2026
Pamiparib (BGB-290)
Poly [ADP-ribose] polymerase-1 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor
PARP1, PARP2Phase 3Ovarian Cancer; Locally Advanced Prostate Cancer; Head and Neck Cancer; GlioblastomaJan 2027
Alcestobart (LBL-007)–Phase 2Non-small Cell Lung Cancer; Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal CancerDec 2026
BGB-11417 (sonrotoclax)
BCL2 inhibitor
BCL2Phase 2Leukemia; MCL; Chronic Lymphocytic Leukemia (CLL)Aug 2027
BGB-A445
anti-NECTIN4 antibody-drug conjugate
NECTIN4Phase 2Non-small Cell Lung Cancer; Urothelial Carcinoma–
BG-68501
Cyclin-dependent kinase-2 inhibitor
CDK2Phase 1Breast CancerAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05661955Tislelizumab (A317)Phase 1Urothelial CarcinomaOncologyMay 2025
NCT05661955BGB-A445Phase 1Urothelial CarcinomaOncologyMay 2025
NCT05635708Alcestobart (LBL-007)Phase 2Non-small Cell Lung CancerOncologyDec 2025
NCT05635708Tislelizumab (A317)Phase 2Non-small Cell Lung CancerOncologyDec 2025
NCT05635708BGB-A445Phase 2Non-small Cell Lung CancerOncologyDec 2025
NCT03736889Tislelizumab (A317)Phase 2MSI-H/dMMR Solid TumorsOncologyNov 2026
NCT05609370Alcestobart (LBL-007)Phase 1Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal CancerOncologyDec 2026
NCT05609370Tislelizumab (A317)Phase 1Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal CancerOncologyDec 2026
NCT03519230Pamiparib (BGB-290)Phase 3Ovarian CancerOncologyJan 2027
NCT05652283Pamiparib (BGB-290)Phase 2Ovarian CancerOncologyMar 2027
NCT04379635Tislelizumab (A317)Phase 3Non Small Cell Lung CancerOncologyMar 2027
NCT03967977Tislelizumab (A317)Phase 3Urothelial CarcinomaOncologyJun 2027
NCT05479994BGB-11417 (sonrotoclax)Phase 2LeukemiaOncologyAug 2027
NCT06257264BG-68501Phase 1Breast CancerOncologyAug 2027
NCT05526924Pamiparib (BGB-290)Phase 1Head and Neck CancerOncologyJan 2028
NCT06463691BGB-11417 (sonrotoclax)Phase 2MCLOncologyDec 2028
NCT06387056Pamiparib (BGB-290)Phase 2Locally Advanced Prostate CancerOncologyApr 2029
NCT03749187Pamiparib (BGB-290)Phase 1GlioblastomaOncologyJul 2029
NCT07508995BGB-11417 (sonrotoclax)Phase 2Chronic Lymphocytic Leukemia (CLL)OncologyJul 2031

Targets

CDK2 (1) BCL2 (1) PARP1 (1) PARP2 (1) PDCD1 (1) NECTIN4 (1)

Companies with the same targets

AstraZeneca Akeso Merck & Co. (MSD) Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group AbbVie Ascentage Pharma Group BeOne Medicines Pfizer GSK

Companies built like this

CSPC Megalith Biopharmaceutical Lepu Biopharma Chipscreen Biosciences Akeso Arcus Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.